Skip to main content
. 2020 Aug 10;9(19):6972–6983. doi: 10.1002/cam4.3331

Figure 2.

Figure 2

PI16 knockdown potentiates sorafenib response in HCC. (A and B) Representative flow cytometry images of Annexin V‐PI staining and quantification of net apoptosis in PI16 knockdown MHCC‐97H cells treated with 5 μM Sorafenib and 10 μM Sorafenib. (C and D) Representative flow cytometry images of Annexin V‐PI staining and quantification of net apoptosis in PI16 overexpressed HepG2 cells treated with 5 μM Sorafenib and 10 μM Sorafenib. (E) Cell cytotoxicity LDH assay of PI16 knockdown, overexpression and negative controls in both 97H and HepG2 cells treated with 5 μM Sorafenib and 10 μM Sorafenib. (F and G) PI16 expression in wild‐type MHCC‐97H and HepG2 cells after 5 μM Sorafenib treatment; β‐actin was used as a control. **P < .01, ***P < .001, Student's t test